MicroRNAs in ovarian carcinomas.

Plasma microRNAs as novel biomarkers for endometriosis and endometriosis-associated ovarian cancer. Clin Cancer Res (2013) 2.15

Discovery of multi-dimensional modules by integrative analysis of cancer genomic data. Nucleic Acids Res (2012) 1.46

A microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis. Proc Natl Acad Sci U S A (2013) 1.44

microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nat Commun (2014) 1.41

Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nat Commun (2013) 1.36

HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes. Cancer Res (2011) 1.27

Repertoire of porcine microRNAs in adult ovary and testis by deep sequencing. Int J Biol Sci (2011) 1.22

Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes. Br J Cancer (2013) 1.21

Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer. Oncol Rep (2012) 1.16

Gain-of-function microRNA screens identify miR-193a regulating proliferation and apoptosis in epithelial ovarian cancer cells. Int J Oncol (2013) 1.06

Transcription factor-microRNA-target gene networks associated with ovarian cancer survival and recurrence. PLoS One (2013) 1.06

Clinically relevant microRNAs in ovarian cancer. Mol Cancer Res (2014) 1.01

Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker. BMC Cancer (2014) 0.99

Insights into the field carcinogenesis of ovarian cancer based on the nanocytology of endocervical and endometrial epithelial cells. Int J Cancer (2013) 0.97

Ovarian cancer biomarker discovery based on genomic approaches. J Cancer Prev (2013) 0.84

MicroRNA signature of cis-platin resistant vs. cis-platin sensitive ovarian cancer cell lines. J Ovarian Res (2011) 0.83

MicroRNAs in ovarian function and disorders. J Ovarian Res (2015) 0.83

MicroRNAs 125a and 125b inhibit ovarian cancer cells through post-transcriptional inactivation of EIF4EBP1. Oncotarget (2016) 0.83

Current clinical application of serum biomarkers to detect ovarian cancer. Prz Menopauzalny (2015) 0.82

The miR-200 Family: Versatile Players in Epithelial Ovarian Cancer. Int J Mol Sci (2015) 0.81

Network analysis of microRNAs and their regulation in human ovarian cancer. BMC Syst Biol (2011) 0.81

[Pathobiology of the microRNA system]. Pathologe (2012) 0.80

miR-30a inhibits endothelin A receptor and chemoresistance in ovarian carcinoma. Oncotarget (2016) 0.80

The LIN28/let-7 Pathway in Cancer. Front Genet (2017) 0.79

A syntenic locus on buffalo chromosome 20: novel genomic hotspot for miRNAs involved in follicular-luteal transition. Funct Integr Genomics (2016) 0.77

Ovarian cancer: emerging molecular-targeted therapies. Biologics (2012) 0.77

Stress induced premature senescence: a new culprit in ovarian tumorigenesis? Indian J Med Res (2014) 0.77

Potential Coagulation Factor-Driven Pro-Inflammatory Responses in Ovarian Cancer Tissues Associated with Insufficient O₂ and Plasma Supply. Int J Mol Sci (2017) 0.75

MiR-31 and miR-128 regulates poliovirus receptor-related 4 mediated measles virus infectivity in tumors. Mol Oncol (2016) 0.75

MiR-338-3p targets pyruvate kinase M2 and affects cell proliferation and metabolism of ovarian cancer. Am J Transl Res (2016) 0.75

Identification of common oncogenic and early developmental pathways in the ovarian carcinomas controlling by distinct prognostically significant microRNA subsets. BMC Genomics (2017) 0.75

MicroRNAs: genomics, biogenesis, mechanism, and function. Cell (2004) 198.59

MicroRNA expression profiles classify human cancers. Nature (2005) 69.12

The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell (1993) 64.62

Prediction of mammalian microRNA targets. Cell (2003) 53.70

Combinatorial microRNA target predictions. Nat Genet (2005) 50.48

Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature (2005) 48.95

MicroRNA signatures in human cancers. Nat Rev Cancer (2006) 46.29

A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09

MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol Cell (2007) 38.42

Human MicroRNA targets. PLoS Biol (2004) 34.51

The impact of microRNAs on protein output. Nature (2008) 32.39

Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2002) 32.26

Widespread changes in protein synthesis induced by microRNAs. Nature (2008) 31.44

RAS is regulated by the let-7 microRNA family. Cell (2005) 30.24

Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29

A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med (2005) 26.02

miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A (2005) 21.51

A microRNA component of the p53 tumour suppressor network. Nature (2007) 19.25

Fast and effective prediction of microRNA/target duplexes. RNA (2004) 18.10

Switching from repression to activation: microRNAs can up-regulate translation. Science (2007) 17.00

Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet (2007) 15.46

Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell (2007) 14.58

Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes. RNA (2005) 14.14

MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods (2007) 13.94

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med (1996) 11.72

MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol (2008) 11.46

Retracted A pleiotropically acting microRNA, miR-31, inhibits breast cancer metastasis. Cell (2009) 10.51

Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol (2008) 10.28

Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell (2007) 9.51

MicroRNA signatures in human ovarian cancer. Cancer Res (2007) 9.45

Transcription and processing of human microRNA precursors. Mol Cell (2004) 8.98

Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell (2006) 8.46

TarBase: A comprehensive database of experimentally supported animal microRNA targets. RNA (2005) 8.40

Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA (2004) 8.31

microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A (2006) 8.24

Sequence-specific inhibition of small RNA function. PLoS Biol (2004) 7.98

Sequence-specific inhibition of microRNA- and siRNA-induced RNA silencing. RNA (2004) 7.71

MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res (2008) 7.45

MicroRNA-cancer connection: the beginning of a new tale. Cancer Res (2006) 7.38

Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G1-arrest. Cell Cycle (2007) 7.00

Suppression of non-small cell lung tumor development by the let-7 microRNA family. Proc Natl Acad Sci U S A (2008) 6.89

MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene (2007) 6.55

miR2Disease: a manually curated database for microRNA deregulation in human disease. Nucleic Acids Res (2008) 6.30

Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J (2007) 6.26

Biological principles of microRNA-mediated regulation: shared themes amid diversity. Nat Rev Genet (2008) 5.83

MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res (2008) 5.54

DIANA-microT web server: elucidating microRNA functions through target prediction. Nucleic Acids Res (2009) 5.23

A biochemical approach to identifying microRNA targets. Proc Natl Acad Sci U S A (2007) 5.16

MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res (2007) 4.95

Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci U S A (2008) 4.79

Mammalian miRNA RISC recruits CAF1 and PABP to affect PABP-dependent deadenylation. Mol Cell (2009) 4.57

The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol (2008) 4.10

miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther (2007) 3.93

Structural requirements for pre-microRNA binding and nuclear export by Exportin 5. Nucleic Acids Res (2004) 3.81

Biological basis for restriction of microRNA targets to the 3' untranslated region in mammalian mRNAs. Nat Struct Mol Biol (2009) 3.70

Let-7 and miR-200 microRNAs: guardians against pluripotency and cancer progression. Cell Cycle (2009) 3.68

Let-7 prevents early cancer progression by suppressing expression of the embryonic gene HMGA2. Cell Cycle (2007) 3.62

Let-7 expression defines two differentiation stages of cancer. Proc Natl Acad Sci U S A (2007) 3.59

The deep evolution of metazoan microRNAs. Evol Dev (2009) 3.56

Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications. Nat Rev Genet (2009) 3.09

MicroRNAs: novel biomarkers for human cancer. Clin Chem (2009) 2.97

Detection of cancer with serum miRNAs on an oligonucleotide microarray. PLoS One (2009) 2.68

MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One (2008) 2.60

miRGator: an integrated system for functional annotation of microRNAs. Nucleic Acids Res (2007) 2.59

Role of microRNAs in drug-resistant ovarian cancer cells. Gynecol Oncol (2008) 2.56

Potential role of miR-9 and miR-223 in recurrent ovarian cancer. Mol Cancer (2008) 2.53

Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor-II expression and favorable prognosis. Cancer Res (2007) 2.45

Repertoire of microRNAs in epithelial ovarian cancer as determined by next generation sequencing of small RNA cDNA libraries. PLoS One (2009) 2.37

MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Res (2008) 2.35

A functional polymorphism in the miR-146a gene and age of familial breast/ovarian cancer diagnosis. Carcinogenesis (2008) 2.31

A miR-200 microRNA cluster as prognostic marker in advanced ovarian cancer. Gynecol Oncol (2009) 2.26

A microRNA cluster as a target of genomic amplification in malignant lymphoma. Leukemia (2005) 2.19

A bioinformatics tool for linking gene expression profiling results with public databases of microRNA target predictions. RNA (2008) 2.16

Identification of miRNA targets with stable isotope labeling by amino acids in cell culture. Nucleic Acids Res (2006) 1.97

MicroRNAs in tumorigenesis: a primer. Am J Pathol (2007) 1.83

Natural history and prognosis of untreated stage I epithelial ovarian carcinoma. J Clin Oncol (1996) 1.78

Chemotherapy of ovarian cancer. Semin Oncol (1984) 1.75

Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications. J Clin Invest (2007) 1.72

Isolation of microRNA targets using biotinylated synthetic microRNAs. Methods (2007) 1.69

The RNA-induced silencing complex: a versatile gene-silencing machine. J Biol Chem (2009) 1.65

Prediction of human microRNA targets. Methods Mol Biol (2006) 1.60

Optimal chemotherapy treatment for women with recurrent ovarian cancer. Curr Oncol (2007) 1.55

Design and delivery of antisense oligonucleotides to block microRNA function in cultured Drosophila and human cells. Nat Protoc (2008) 1.38

MicroRNA reexpression as differentiation therapy in cancer. J Clin Invest (2009) 1.38

An intronic microRNA silences genes that are functionally antagonistic to its host gene. Nucleic Acids Res (2008) 1.27

Fertility preservation in young women with epithelial ovarian cancer. Cancer (2009) 1.24

A novel method to detect functional microRNA targets. J Mol Biol (2006) 1.11

Labeled microRNA pull-down assay system: an experimental approach for high-throughput identification of microRNA-target mRNAs. Nucleic Acids Res (2009) 1.09

Proteomics joins the search for microRNA targets. Cell (2008) 1.02

Human microRNA target analysis and gene ontology clustering by GOmir, a novel stand-alone application. BMC Bioinformatics (2009) 1.00

Elevated serum-circulating RNA in patients with conventional renal cell cancer. Anticancer Res (2008) 0.85

Five-year survival for stage IC or stage I grade 3 epithelial ovarian cancer treated with cisplatin-based chemotherapy. Gynecol Oncol (1992) 0.82

An anatomy of normal and malignant gene expression. Proc Natl Acad Sci U S A (2002) 4.45

The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer (2006) 2.61

MicroRNA expression and identification of putative miRNA targets in ovarian cancer. PLoS One (2008) 2.60

Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res (2008) 2.26

Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res (2005) 2.07

Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res (2003) 2.01

Bacteroides fragilis enterotoxin induces c-Myc expression and cellular proliferation. Gastroenterology (2003) 1.86

Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell (2003) 1.81

Identifying tumor origin using a gene expression-based classification map. Cancer Res (2003) 1.78

The claudins. Genome Biol (2009) 1.76

A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival. Proc Natl Acad Sci U S A (2006) 1.52

Phosphorylation of claudin-3 at threonine 192 by cAMP-dependent protein kinase regulates tight junction barrier function in ovarian cancer cells. J Biol Chem (2005) 1.49

Activation of fatty acid synthesis during neoplastic transformation: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Exp Cell Res (2002) 1.47

Claudin-containing exosomes in the peripheral circulation of women with ovarian cancer. BMC Cancer (2009) 1.44

Crucial roles of Sp1 and epigenetic modifications in the regulation of the CLDN4 promoter in ovarian cancer cells. J Biol Chem (2006) 1.25

Filamin A-mediated down-regulation of the exchange factor Ras-GRF1 correlates with decreased matrix metalloproteinase-9 expression in human melanoma cells. J Biol Chem (2007) 1.23

Regulation of fatty acid synthase expression in breast cancer by sterol regulatory element binding protein-1c. Exp Cell Res (2003) 1.23

Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. Cancer Res (2005) 1.22

Generation and analysis of melanoma SAGE libraries: SAGE advice on the melanoma transcriptome. Oncogene (2004) 1.18

A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development. J Pathol (2014) 1.17

Phosphorylation of claudin-4 by PKCepsilon regulates tight junction barrier function in ovarian cancer cells. Exp Cell Res (2007) 1.12

Silencing of claudin-11 is associated with increased invasiveness of gastric cancer cells. PLoS One (2009) 1.10

Molecular mechanisms of platinum resistance: still searching for the Achilles' heel. Drug Resist Updat (2004) 1.07

The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation. Breast Cancer Res (2012) 1.07

Development of a highly specialized cDNA array for the study and diagnosis of epithelial ovarian cancer. Cancer Res (2002) 1.07

Regulation of the CLDN3 gene in ovarian cancer cells. Cancer Biol Ther (2007) 1.04

Gene expression and pathway analysis of ovarian cancer cells selected for resistance to cisplatin, paclitaxel, or doxorubicin. J Ovarian Res (2011) 1.04

Claudin-3 and claudin-4 expression in serous papillary, clear-cell, and endometrioid endometrial cancer. Gynecol Oncol (2008) 1.04

Identification of intelectin overexpression in malignant pleural mesothelioma by serial analysis of gene expression (SAGE). Lung Cancer (2004) 1.03

Loss of Klotho during melanoma progression leads to increased filamin cleavage, increased Wnt5A expression, and enhanced melanoma cell motility. Pigment Cell Melanoma Res (2010) 1.00

Characterization of novel human ovarian cancer-specific transcripts (HOSTs) identified by serial analysis of gene expression. Oncogene (2003) 1.00

Age-related changes of claudin expression in mouse liver, kidney, and pancreas. J Gerontol A Biol Sci Med Sci (2009) 0.92

Claudin-7 is frequently overexpressed in ovarian cancer and promotes invasion. PLoS One (2011) 0.91

Anomalous expression of the HLA-DR alpha and beta chains in ovarian and other cancers. Cancer Biol Ther (2004) 0.90

Serial analysis of gene expression in renal carcinoma cells reveals VHL-dependent sensitivity to TNFalpha cytotoxicity. Oncogene (2002) 0.90

Serial analysis of gene expression reveals differential expression between endometriosis and normal endometrium. Possible roles for AXL and SHC1 in the pathogenesis of endometriosis. Reprod Biol Endocrinol (2008) 0.89

Fat-storing multilocular cells expressing CCR5 increase in the thymus with advancing age: potential role for CCR5 ligands on the differentiation and migration of preadipocytes. Int J Med Sci (2009) 0.85

Possible angiogenic roles for claudin-4 in ovarian cancer. Cancer Biol Ther (2009) 0.82

Dietary methionine restriction improves colon tight junction barrier function and alters claudin expression pattern. Am J Physiol Cell Physiol (2010) 0.82

Non-steroidal anti-inflammatory drugs decrease E2F1 expression and inhibit cell growth in ovarian cancer cells. PLoS One (2013) 0.81

Novel MicroRNA Reporter Uncovers Repression of Let-7 by GSK-3β. PLoS One (2013) 0.78